Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 390,397,696
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 23,461 M
  • 60-Month Beta 0.35
  • Price/Sales 6.43
  • Price/Cash Flow 14.90
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 26.78% (-0.31%)
  • Historical Volatility 29.91%
  • IV Percentile 54%
  • IV Rank 27.10%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 8) 6.33 (2.78%)
  • Put/Call Vol Ratio 0.69
  • Today's Volume 14,598
  • Volume Avg (30-Day) 49,352
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 231,802
  • Open Int (30-Day) 227,555
  • Expected Range 221.17 to 233.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.02
  • Number of Estimates 7
  • High Estimate 3.17
  • Low Estimate 2.97
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.27 +11.37%
on 02/04/26
229.79 -0.99%
on 02/02/26
+7.46 (+3.39%)
since 01/12/26
3-Month
204.27 +11.37%
on 02/04/26
239.29 -4.93%
on 11/13/25
-5.73 (-2.46%)
since 11/12/25
52-Week
164.39 +38.39%
on 04/09/25
244.81 -7.07%
on 10/01/25
+34.50 (+17.88%)
since 02/12/25

Most Recent Stories

More News
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

ABBV : 227.50 (+2.99%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 5.92 (-8.78%)
AZN : 204.52 (-0.12%)
JNJ : 244.55 (+1.53%)
HELP.NE : 8.0800 (-8.49%)
ABBV : 227.50 (+2.99%)
TAK : 18.37 (+0.49%)
3 Market-Beating Stocks to Research Further

3 Market-Beating Stocks to Research Further

CCB : 83.49 (-4.72%)
BX : 129.77 (-2.77%)
ABBV : 227.50 (+2.99%)
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

ABT : 111.47 (-1.87%)
ABBV : 227.50 (+2.99%)
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

ABBV : 227.50 (+2.99%)
AbbVie: Q4 Earnings Snapshot

AbbVie: Q4 Earnings Snapshot

ABBV : 227.50 (+2.99%)
AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

ABBV : 227.50 (+2.99%)
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

NORTH CHICAGO, Ill. , Feb. 4, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025.

ABBV : 227.50 (+2.99%)
Stock Index Futures Steady After Tech-Led Selloff, U.S. ADP Jobs Report and Alphabet Earnings in Focus

March S&P 500 E-Mini futures (ESH26) are up +0.11%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.01% this morning, steadying after yesterday’s tech-led selloff, while investors await the U.S....

ACA.FP : 17.940 (-0.50%)
GOOGL : 309.00 (-0.63%)
BSX : 74.12 (+0.88%)
SMCI : 30.43 (-5.02%)
MU : 413.97 (+0.88%)
TRI : 85.89 (-3.71%)
IT : 153.63 (-4.89%)
ABBV : 227.50 (+2.99%)
ESH26 : 6,858.50 (+0.11%)
NOVOB.C.DX : 308.050 (+0.75%)
QCOM : 138.47 (-1.82%)
EPAM : 163.12 (-8.35%)
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

IRVINE, Calif. , Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle ® Testimonial Program...

ABBV : 227.50 (+2.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 238.87
2nd Resistance Point 233.96
1st Resistance Point 230.73
Last Price 227.50
1st Support Level 222.59
2nd Support Level 217.68
3rd Support Level 214.45

See More

52-Week High 244.81
Last Price 227.50
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar